Dr. Michael Offin, MD
Internal Medicine (Internal Medicine Physician)
- Medicare participating
At a glance
- Years since graduation
- 13
- In the NPI registry since
- 2013
- Medicare patients seen, 2024
- 194
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2013Registered with an NPI (national billing number; not a license date)
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Internal Medicine Physician primary
PA license MT203693
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Memorial Solid Tumor Group (234 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 194
- Services billed
- 869
- Patients’ average age
- 75
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 314 | 71 |
| Established patient office or other outpatient visit, 20-29 minutes | 134 | 62 |
| New patient office or other outpatient visit, 60-74 minutes | 56 | 56 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 53 | 23 |
| Established patient office or other outpatient visit, 40-54 minutes | 48 | 37 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Tagrisso (osimertinib mesylate) | 82 |
| Dexamethasone Other prescribers in New York, NY | 76 |
| Ondansetron Hcl Other prescribers in New York, NY | 40 |
| Prednisone Other prescribers in New York, NY | 29 |
| Levothyroxine Sodium Other prescribers in New York, NY | 24 |
| Oxycodone Hcl Other prescribers in New York, NY | 19 |
| Pantoprazole Sodium Other prescribers in New York, NY | 19 |
| Folic Acid Other prescribers in New York, NY | 17 |
| Mirtazapine Other prescribers in New York, NY | 17 |
| Alecensa (alectinib hcl) | 17 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 5 companies reported 7 payments worth $107,469 in total to this clinician.
| Genentech, Inc. | $100,000 |
|---|---|
| Servier Bioinnovation | $3,400 |
| Pfizer Inc. | $2,655 |
| AstraZeneca Pharmaceuticals LP | $1,335 |
| AstraZeneca UK Limited | $78.92 |
| Grant | $100,000 |
|---|---|
| Consulting Fee | $7,120 |
| Food and Beverage | $349 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genentech, Inc. Oct 15, 2025 | Grant | $100,000 |
| Servier Bioinnovation Nov 25, 2025 | Consulting Fee | $3,400 |
| Pfizer Inc. Jun 20, 2025 | Consulting Fee LORBRENA · ONCOLOGY | $2,520 |
| AstraZeneca Pharmaceuticals LP Nov 11, 2025 | Consulting Fee | $1,200 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 4 industry-funded studies in 2025, from 4 companies. The companies reported $936,779 in research payments for these studies, mostly to the institutions running them.
- Phase 2 study of sacituzumab govitecan-hziyin in patients with previously treated mesotheliomas
Gilead Sciences, Inc. - A Phase III, Randomized, Open-Label, Multicenter, Global Study of Volrustomig (MEDI5752) in Combination with Carboplatin plus Pemetrexed Versus Platinum plus Pemetrexed or Nivolumab plus Ipilimumab in Participants wit…
AstraZeneca Pharmaceuticals LP - A phase 2 openlabel study of encorafenib binimetinib in patients with BRAFV600MUTANT nonsmall cell lung cancer
Array Biopharma Inc - A Phase Ib open label multicenter study of oral LXH254 in combination with oral LTT462 in adult patients with advanced or metastatic KRAS or BRAF mutant Non Small Cell Lung Cancer
Novartis Pharmaceuticals Corporation
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.